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Introduction
Viral infections cause morbidity and mortality in immunosup-
pressed patients following allogeneic hematopoietic stem cell 
transplantation (HSCT) (1). This principally reflects the inability 
of the depressed host immune system to limit viral replication and 
dissemination, and loss of T cell function is central to this effect 
(2). Despite advances in prophylactic and preemptive pharmaco-
therapy, antiviral therapeutics are limited by toxicity and to some 
extent by lack of efficacy in breakthrough infections (3). Immu-
notherapeutic strategies to accelerate reconstitution of virus- 
specific immunity and to hasten T cell recovery after HSCT remain 
a compelling alternative to drug treatments. This Review will dis-
cuss cytomegalovirus (CMV) and Epstein-Barr virus (EBV) in the 
post-HSCT setting, with a focus on CMV- and EBV-directed virus- 
specific T cells (VSTs). Published data additionally support the use 
of VSTs in the settings of solid organ transplantation and profound 
non-HSCT immunosuppression (4–6), but detailed discussion 
is beyond the scope of the Review. Emerging evidence supports 
the use of VSTs to treat a broader range of viral targets, including 
varicella-zoster virus, adenovirus, and BK virus. Cutting-edge 
translation of this multi-VST technology will be reviewed (7–9).
CMV: biology and pathogenicity in the post-HSCT setting. CMV 
infects 50%–80% of the population and maintains a latent reser-
voir in mononuclear leukocytes. Containment of CMV in its latent 
state engages a large proportion of the host immune repertoire: in 
young adults, 1%–2% of CD4 and CD8 T cells are CMV-reactive, 
rising to up to 30%–40% in the elderly (10–13). For the majority 
of CMV-infected individuals, asymptomatic reactivation is coun-
tered effectively by innate and adaptive immunity. In the immu-
nocompromised HSCT patient, unconstrained viral replication 
and dissemination can lead to end-organ damage, CMV disease, 
and increased mortality (14, 15). The efficacy of conventional 
antiviral therapies such as ganciclovir and foscarnet to treat CMV 
end-organ disease is limited (16).
Sixty to eighty-five percent of CMV-seropositive patients will 
experience CMV dissemination after HSCT, particularly in the con-
text of T cell–depleted or matched unrelated donor (MUD) grafts. In 
CMV-seronegative patients, primary infection is prevented through 
selection of CMV-seronegative grafts (17), but where matched 
CMV-seronegative donors are unavailable, 20%–40% of CMV- 
seronegative patients who receive CMV-seropositive grafts will 
develop primary CMV infection. Untreated, 50% of HSCT patients 
with CMV reactivation will develop CMV disease (14, 15).
Current clinical practice uses surveillance programs to monitor 
CMV DNA burden by quantitative PCR (16, 18). Preemptive anti-
viral pharmacotherapy (asymptomatic patients with rising CMV 
DNA titers) and prophylactic therapy (pharmacotherapy prior 
to detection of CMV DNA) can reduce the incidence of CMV 
disease after HSCT, but have not yet definitively correlated with 
improved overall survival (18–20). An additional consideration of 
prophylactic/preemptive pharmacotherapy for CMV is that drug 
toxicities (including neutropenia with consequent bacterial infec-
tion, and renal impairment) and to a lesser extent drug resistance 
remain problematic. Novel antiviral pharmacotherapies are under 
investigation (e.g., maribavir, letermovir, brincidofovir) but have 
not yet clearly demonstrated superiority/lesser toxicity compared 
with conventional agents (21, 22).
Immunotherapeutic strategies to hasten T cell recovery 
after HSCT remain a compelling alternative/adjunct to drug 
treatments. European Blood and Marrow Transplant Registry 
data report a reduction in transplant-related and overall mortal-
ity when CMV-seropositive patients receive CMV-seropositive 
grafts. In contrast, CMV-seropositive patients in receipt of T 
cell–depleted CMV-seronegative donor or cord blood grafts are 
at highest risk from CMV-associated morbidity and mortality 
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections following allogeneic hematopoietic stem cell transplantation 
(HSCT) are a major cause of morbidity and mortality. Early clinical trials demonstrate that adoptive transfer of donor-
derived virus-specific T cells to restore virus-specific immunity is an effective strategy to control CMV and EBV infection 
after HSCT, conferring protection in 70%–90% of patients. The field has evolved rapidly to develop solutions to some of the 
manufacturing challenges identified in early clinical studies, such as prolonged in vitro culture, optimization of the purity of 
the virus-specific T cell product, the potential limitations of targeting a single viral antigen, and how to manage the patient 
with a virus-naive donor. This Review both discusses the seminal early studies and explores cutting-edge novel technologies 
that broaden the feasibility of and the scope for delivering virus-specific T cells to patients after HSCT.
Immunotherapy for transplantation-associated  
viral infections
Claire Roddie1,2 and Karl S. Peggs1,2
1Department of Haematology, University College London Cancer Institute, London, United Kingdom. 2Department of Haematology, University College London Hospitals NHS Foundation Trust,  
London, United Kingdom.
Conflict of interest: K.S. Peggs is a founder member of and shareholder in Achilles 
Therapeutics, and a consultant for Autolus.
Reference information: J Clin Invest. 2017;127(7):2513–2522. 
https://doi.org/10.1172/JCI90599.
Downloaded from http://www.jci.org on July 31, 2017.   https://doi.org/10.1172/JCI90599
The Journal of Clinical Investigation R E V I E W  S E R I E S :  T R A N S P L A N T A T I O N
2 5 1 4 jci.org   Volume 127   Number 7   July 2017
In one study of 33 volunteers exposed 
to overlapping 15-mer peptides derived 
from 213 CMV ORFs, immune reactivity 
to 151 of the 213 ORFs was demonstrated. 
CMV-seropositive subjects recognize a 
median of 12 (CD4) and 8 (CD8) CMV 
ORFs, which amounts to a circulating 
CMV memory repertoire of greater than 
20% in at least one-third of older sub-
jects (26). This broadens the list of CMV- 
specific target antigens beyond the current 
gold standards pp65 and IE-1.
In healthy subjects, CMV replication is 
effectively contained by the innate and adap-
tive immune systems. Neutralizing antibod-
ies to envelop glycoprotein B (27) can prevent 
blood-borne spread, but in general, humoral 
responses to CMV confer limited protection 
(25). In contrast, preclinical studies confirm 
that CMV-specific T cells are critical to recov-
ery from CMV infection: CD8 T cells can pre-
vent CMV recurrence, and CD4 T cells can 
deliver antiviral functions such as cytotoxic-
ity and cytokine production (25, 28).
In CMV-seropositive HSCT patients, the risk of viremia 
inversely correlates with reconstitution of CMV-specific T cell 
immunity. The frequency of CMV-specific T cells identified within 
a graft correlates inversely with reported CMV infection after 
HSCT (29, 30), and reconstitution of CMV-reactive CD8 T cells 
is associated with protection against CMV (31). In one study of T 
cell–replete sibling allograft recipients where recipient and donor 
were CMV seropositive, CMV reactivation was followed by rapid 
CMV-reactive CD8 T cell reconstitution, and the presence of more 
than 10 CMV-reactive CD8 T cells/μl blood was associated with 
protective immunity. This was not observed in a matched cohort 
of CMV-seropositive recipients treated with CMV-seronegative 
grafts (29). Recovery of CMV-specific CD4 responses is also criti-
cal to effective antiviral responses, and several groups have advo-
cated for restoration of both antigen-specific CD4 and CD8 T cell 
populations to deliver long-term control of CMV (32).
(23, 24). Patients with severe graft-versus-host disease (GVHD) 
and drug-induced T cell dysfunction are also at high risk of 
CMV-related morbidity.
We can conclude that pharmacotherapy for CMV has limita-
tions, that transfer/reconstitution of CMV immunity can limit 
reactivation/dissemination of CMV, and that CMV-seropositive 
HSCT patients stand to benefit significantly from VSTs.
CMV: immune responses in health and disease. To determine 
optimal approaches to T cell therapies for CMV, it is pertinent to 
review the immune response to primary infection/viral reactiva-
tion. The CMV virion comprises a 230-kb double-stranded lin-
ear DNA genome encapsulated by a protein-rich tegument with 
abundant pp150 (U32) and pp65 (UL83) proteins. During the 
infective phase, three subgroups of viral proteins are synthesized: 
immediate-early (IE), early (E), and late (L) (25). The breadth of 
T cell responses to CMV in healthy subjects is heterogeneous. 
Figure 1. VST manufacture and direct selection 
methodology. VSTs can be generated by coculture 
of virus-derived peptides, proteins, or viral lysates 
with antigen-presenting cells (APCs) and T cells. 
However, these techniques are time-consuming 
and difficult to reproduce to good manufacturing 
practice (GMP) standards. Recently developed 
coculture methods include the use of gene- 
modified APCs that are engineered to present 
immunogenic viral peptides to T cells. This 
may allow for the generation of virus-reactive 
T cells from virus-naive donors. Direct selection 
techniques can permit rapid generation of VSTs to 
GMP standards and are now being used in clinical 
trials. Selection is delivered through IFN-γ capture 
or through multimer-based selection. LCL, lym-
phoblastoid cell lines; MoDC, monocyte-derived 
dendritic cell; LDA, limiting dilution assay.
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tive therapy. Outcomes have been encouraging, but comparisons 
between studies are difficult because of both the heterogeneous 
composition of the cell products (namely CD4/CD8 ratio, total cell 
dose, and range of CMV-target specificities) and the highly vari-
able study design (timing of infusion, preemptive versus prophy-
lactic administration, patient CMV risk group) (33–37). See Table 
1 for an overview of clinical studies of CMV-specific T cells after 
HSCT and Figure 1 for a schematic illustration of different meth-
ods of VST manufacture, including direct selection methodology.
CMV-specific T cell clones. Initial clinical studies used CMV- 
specific T cell clones to reduce the potential risk of GVHD. In one 
study, large numbers of donor-derived CD8 T cell clones expanded 
for over 8 weeks in vitro by repeated restimulation were infused at 
day 30–40 after HSCT into low-risk patients. Encouragingly, CD8 T 
cell expansion was observed, but was not maintained in the absence 
Cellular therapies for CMV
A number of considerations help guide appropriate use of VSTs in 
post-HSCT patients. Prophylactic therapy poses several challenges: 
it will expose some patients to unnecessary therapy with the atten-
dant risks of T cell alloreactivity and GVHD, it may not be feasi-
ble from a health economics perspective because of a costly cell 
manufacture process, and it is not yet clear whether the absence 
of antigenic stimulation from replicating virus may compromise 
engraftment/expansion of VSTs in vivo.
Preemptive therapy based on PCR-directed surveillance 
will reduce overtreatment. Concerns mainly relate to deliver-
ability and, in particular, whether good manufacturing practice– 
compliant (GMP-compliant) technology can generate VSTs at the 
tempo required for effective clinical application (25). The major-
ity of published clinical studies describe prophylactic or preemp-
Table 1. Clinical studies of donor-derived CMV-specific T cells
Cell therapy No. of patients Date of study Activation Acute GVHD Dose CMV-related outcome Ref.A
CD8 T cell clones 14 1995 Autologous fibroblasts 
pulsed with CMV virion 
proteins 
3 Grade 1–2 
GVHD
Intrapatient dose 
escalation; range 33 × 
106/m2 to 1 × 109/m2
Reconstitution CMV immunity  
in 14/14
38
Polyclonal T cell lines 8 2002 CMV lysate None 1 × 107 T cells/m2 5/8 cleared after dose 1; 1/8 cleared 
after dose 2; 1/8 did not clear; 1/8 
non-evaluable
36
Polyclonal T cell lines 16 2003 CMV Ag-pulsed DCs 3 Grade 1 skin 
GVHD
1 × 105/kg 8/16 cases did not require antiviral 
drugs; further reactivation in  
2/16 only
34
CD8 T cells (multimer selected) 9 2005 NLV-HLA-A02 
pentamers
2 Grade 1–2 
GVHD
1.23 × 103/kg to 3.3 × 
104/kg
8/9 cleared viremia 51
CD4 T cell clones 25 2005 CMV antigen 1 Grade 2 GVHD 1 × 105/kg to 1 × 106/kg 7/25 reactivated CMV; 5/25 CMV 
disease (2 died)
39
Polyclonal T cell lines 9 2007 NLVPMVATV (HLA-A2 
restricted) pulsed DCs
3 Grade 3 GVHD 
(fatal in 1)
Target dose 2 × 107/m2 Transient detection CMV-specific T 
cells by NLV-tetramer staining; 2/9 
reactivated CMV without requirement 
antiviral drugs 
37
Polyclonal T cell lines 12 2008 DCs transduced 
with Ad5f35pp65 
adenoviral vector 
encoding CMV-pp65
2 Grade 3; 2 
grade 2 GVHD
2 × 107/m2 Reconstitution CMV immunity  
in 12/12; no requirement for  
antiviral drugs
42
Polyclonal CD4 and CD8 T cells 
(gamma catch)
18 2010 CMV-pp65 protein 1 Possible GVHD Mean dose 21 × 103/kg 
pp65-specific T cells
Partial or complete viral clearance 
in 15/18
55
Polyclonal CD4 and CD8 T cells 
(gamma catch)
18  
(11 preemptive;  
7 prophylactic)
2011 Recombinant pp65 
or overlapping pp65 
peptide pool
5 Grade 1; 2 
grade 2; 1 grade 
3 GVHD
Target dose 1 × 104 CD3 T 
cells/kg
CMV-reactive T cells in 11/11 
preemptively treated patients; 7/7 
patients treated prophylactically did 
not reactivate CMV
56
CD8 T cells (multimer selected) 2 2011 Peptides derived from 
pp65
None 0.37 × 105 to 2.2 × 105 
CMV-pp65-CTL/kg
2/2 complete responses 41
Polyclonal T cell lines 7 2012 Peptides derived from 
IE-1 and pp65
None 2.5 × 105 to 5 × 105 
CD3+CMV CTL/kg
5/7 developed CMV-specific CTL 
activity in the blood; 2/7 no response
81
Polyclonal CD4 and CD8 T cells 
(gamma catch)
6 2012 Two CMV-pp65 
peptides
None 0.6 × 106 to 17 × 106 T 
cells (comprising 54%–
96% CMV-pp65–specific 
CD8 T cells)
6/6 cleared viremia 82
CD8 T cells (multimer selected) 2 2012 NLV-containing HLA-
A02 pentamers
None 0.8 × 104 to 10.8 × 104 
cells/kg
2/2 complete responses 83
Polyclonal T cell lines 16 2015 15-mer peptides 
spanning pp65
None 5 × 105/kg (× 1 dose) to 
1 × 106/kg (× 3 weekly 
doses)
14/16 cleared viremia (including 2 
with CMV disease)
84
ASome cited studies incorporate results of other published studies. Ag, antigen.
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observed (36). In a separate study of preemptive intervention 
following detection of CMV DNAemia by PCR, T cells cocul-
tured over 3 weeks with MoDCs pulsed with CMV lysate were 
infused into patients after HSCT. Outcomes were promising: no 
cases of CMV disease or GVHD were reported, 50% of all treated 
patients cleared the virus without antiviral pharmacotherapy, 
and despite very low cell doses (<1 × 103 CMV T cells/kg), mas-
sive in vivo expansion of transferred cells was observed several 
days after infusion (34).
The HLA-A2–restricted pp65 peptide NLVPMVATV (NLV) 
can be used in lieu of CMV lysate, and in T cell/MoDC cocul-
ture NLV yields a product highly enriched for CMV-reactive CD8 
T cells (62% NLV-specific T cells) compared with CMV lysate/
MoDCs (0.2%–6.5% CMV-specific CD8 T cells) (37). A potential 
disadvantage of this manufacturing process is that the final cell 
product largely comprises terminally differentiated CD8 T cells, 
and a clinical study of this product demonstrated relatively poor 
expansion and a short duration of persistence in vivo (40). Sensi-
tization of allogeneic T cells in vitro to a pool of 15-mer peptides 
spanning pp65 was demonstrated to generate oligoclonal CMV- 
specific T cells to three different peptides. Seventeen patients were 
infused, and in 15 cases CMV viremia was cleared, with oligoclo-
nal CMV-specific T cells persisting for up to 2 years in some cases 
of CD4 help, and the logistics of this prolonged manufacture were 
costly and nonscalable (38).  A similar study of CMV-reactive CD4 T 
cell clones in the haploidentical HSCT setting resulted in detectable 
CD4 and CD8 CMV-specific responses in treated patients (39). This 
early work confirmed the potential of adoptive therapy for CMV 
after HSCT without apparent complication by GVHD, but high-
lights some of the challenges of manufacture.
CMV-specific T cell lines. An alternative to CMV-specific T cell 
clones is the use of CMV-specific T cell lines. Oligo- or polyclonal 
CMV-reactive T cell cultures are enriched for CMV-reactivity 
by coculture with CMV lysate, proteins, or peptides pulsed onto 
antigen-presenting cells (APCs), either peripheral blood mono-
nuclear cells (PBMCs) (36) or monocyte-derived dendritic cells 
(MoDCs) (35). MoDCs have some distinct advantages in this role 
by virtue of their ability to cross-present via MHC class I to CD8 
T cells, though their inclusion adds a further manufacturing step.
One clinical study of a single infusion of mainly CD4 CMV- 
specific T cells (1 × 107/m2) in patients with persistent CMV 
DNAemia at 4 weeks after pharmacotherapy showed plasma 
CMV clearance in 63% of patients. Critics of this study argue that 
viral loads were modest in half of the patients, that most patients 
were responding to antiviral pharmacotherapy, and that endog-
enous reconstitution was likely to contribute to the responses 
Table 2. Clinical studies using donor-derived multi-VSTs
Cell therapy No. of patients Date of study Activation Acute GVHD Dose CMV-related outcome Ref.
EBV, ADV 14 2009 Monocytes/LCLs transduced 
with ADV vector
3 Skin rashes 5 × 106 to 1.35 × 108 
cells/m2
11 Patients treated 
prophylactically remain 
negative; 2/3 ADV 
infection cleared virus
85
CMV, EBV 3 2010 DCs pulsed with EBV-LMP2, 
CMV-pp65, CMV-IE peptides
1 Grade 1 GVHD Median cell dosage 
0.6 × 106/kg/
infusion
2/2 patients cleared 
virus; 1/1 patient did not 
reactivate virus (patients 
treated prophylactically)
86
CMV-specific or multi-VSTs 
(CMV, EBV, ADV)
40 2013 pp65-pulsed MoDCs or MoDCs 
transfected with Ad5f35pp65 
adenoviral vector encoding 
CMV-pp65
No increase in acute or 
chronic GVHD related to 
viral-specific CTLs
Dose 2 × 107 cells/m2 CTL recipients had CMV 
immune reconstitution and 
less frequent reactivation 
with only 1 case requiring 
pharmacotherapy
87A
Multi-VSTs (CMV, EBV, ADV) 10 2013 DC nucleofection with DNA 
plasmids encoding viral antigen
1 Grade 1 GVHD Dose range 0.5–2 × 
107 cells/m2
Complete viral eradication 
in 8/10
88
Multi-VSTs (CMV, EBV, ADV, 
HHV-6, BK virus)
11 2014 Immunodominant antigen 
pepmixes
1 Stage II skin GVHD Dose range 0.5 × 107 
to 2 × 107 cells/m2
94% Virological and 
clinical response 
(sustained)
7
Multi-VSTs (CMV, EBV, ADV, 
VZV)
10 2015 Ad5f35 encoding CMV-pp65 
(+ selected EBNA-1, LMP EBV 
epitopes; commercial VZV 
vaccine)
3 Grade 2–4 GVHD Dose 2 × 107/m2 VSTs Reconstitution CMV 
immunity in 10/10; 6/10 
reactivated CMV and 1/10 
required antiviral drugs
8
Multi-VSTs (CMV, EBV, ADV) 26 2015 EBV-LCLs transduced with 
Ad5f35pp65 adenoviral vector 
encoding CMV-pp65
2 Skin rashes 5 × 106/m2 to 1 × 
108/m2
10/11 cleared CMV; 5/6 
cleared ADV; 6/6 cleared 
EBV; 1 patient progressed
43
Multi-VSTs (CMV, EBV, ADV) 3 2015 Monocytes/LCLs transduced 
with Ad5f35pp65 adenoviral 
vector encoding CMV-pp65
None reported 5 × 106/m2 to 1 × 
107/m2
Treatment: 1/1 cleared 
virus; prophylaxis: 2/2 no 
reactivation
62
Multi-VSTs (CMV, EBV, ADV) 6 2016 Immunodominant antigen 
pepmixes
1× grade 1 and 1× grade 
2 GVHD
5 × 106/m2 to 4.6 × 
107/m2
Complete response in 2/2 
with EBV and 2/5 with 
CMV
89
AIncorporates results of other published studies. ADV, adenovirus; VZV, varicella-zoster virus.
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ex vivo manufacture. Direct selection is a rapid process resulting 
in an enriched starting material. This helps to avoid or reduce ex 
vivo culture, which may translate into a more cost-effective and 
GMP-compatible manufacturing process.
Direct CMV-reactive T cell selection can be performed in one 
of two ways: binding of class I HLA–peptide multimers (47, 48), or 
selection according to induction of cytokine secretion (often IFN-γ) 
in response to viral proteins/peptides (49). Alternative approaches 
target surface antigens upregulated following presentation of viral 
antigen on some form of APC. The resulting cellular composition 
will differ between methods such that class I HLA multimers will 
select only CD8 T cells, whereas IFN-γ catch (also known as gamma 
catch) technology will deliver a CD4 T cell–skewed product.
Multimer-based selection. Multimer-based T cell selection is 
currently limited to donors who have one of a restricted number 
of HLA-restricting alleles and detectable responses to specific 
immunodominant epitopes. As the technology grows, multimers 
using an increasing number of alleles and epitopes will become 
available. Their mode of action is to display peptide-loaded 
recombinant HLA complexes to T cells, selecting out those with 
T cell receptors (TCRs) of the correct specificity. There are a 
number of cell selection reagents available, including tetramers, 
pentamers, and streptamers. Similar frequencies of multimer- 
positive T cells can be detected following selection using all three 
techniques, but tetramers possess the lowest background signal 
and can potentially deliver the purest product (50).
The first study to demonstrate the feasibility of tetramer-based 
selection of highly purified CMV peptide–specific CD8 T cells from 
the blood of CMV-seropositive donors delivered a therapeutic 
product to nine HSCT patients within 4 hours of cell selection. A 
median dose of 8.6 × 103 CMV-specific CD8 T cells/kg at a median 
purity of 95.6% was infused, and transferred cells remained detect-
able in all patients at 10 days. Four of seven patients treated pre-
emptively did not require concomitant antiviral pharmacotherapy. 
Notably, one patient with antiviral drug–resistant CMV achieved 
disease control within 8 days of infusion (51).
Streptamers possess one major advantage over other forms of 
selection: they bind target reversibly. Reversible target binding is 
achieved through monomeric Strep-tagging of MHC molecules 
loaded with a selected target peptide to which reactive CD8 T cells 
bind with low affinity. Streptamer multimerization at the T cell 
surface through binding of the Strep-Tactin backbone increases 
binding avidity to T cell targets before selection. The subsequent 
addition of biotin, which competitively binds Strep-Tactin with 
higher affinity, displaces Strep-Tactin multimers from the Strep-
tagged MHC molecules bound to CMV-reactive CD8 T cells. In 
this monomeric format, Strep-tagged MHC spontaneously disso-
ciates from the selected CD8 T cells as a result of the low-affinity 
singular bond (48, 52). Two prospective randomized studies using 
these products have been reported in abstract form: CMV-ACE/
ASPECT (NCT01220895, ClinicalTrials.gov) and CMV-IMPACT 
(NCT01077908) (53, 54). Initial results suggest that they may 
enhance the tempo of immune reconstitution compared with an 
untreated control group, and that they may reduce subsequent 
CMV reactivation rates.
IFN-γ catch. Direct selection of antigen-specific cells can be 
performed by IFN-γ catch, whereby short-term antigen stimu-
(41). A major disadvantage of the HLA-A2–restricted NLV peptide 
approach is the restriction of benefit to HLA-A2+ patients only.
This work broadly confirms that generation of CMV-specific 
cell lines is feasible and that infusion is not associated with a sig-
nificant risk of GVHD. There are compelling data to suggest that 
virus-specific transferred T cells can engraft and expand and have 
the potential to mediate clinical responses.
Multispecific T cell lines. Multi-VST lines represent an interest-
ing option to target multiple viral infections using one adoptive cell 
product. Such lines can be manufactured either with APC systems 
similar to those described in the preceding section (using overlap-
ping peptide pools from multiple viruses), or with gene transfer 
approaches. The latter are exemplified by the use of an adenovi-
ral vector encoding the CMV-associated pp65 antigen to trans-
duce APCs (MoDCs and EBV-transformed lymphoblastoid cell 
lines [LCLs]) before coculture with PBMCs or naive cord blood. 
This method delivers both MHC class I–dependent processing 
and expansion of CMV-reactive CD8 T cells, and MHC class II–
dependent processing and presentation of adenovirus/EBV/CMV– 
associated peptides to drive expansion of virus-specific CD4 T cells.
The adenoviral transfer vector promotes antiadenoviral T cell 
specificity (bispecific cytotoxic T lymphocytes [CTLs]) (42), and 
if EBV-transformed B cells are used in lieu of MoDCs, then addi-
tional EBV-specificity is generated (trispecific CTLs) (43). The rel-
ative benefits of trispecific antiviral T cells produced in this way 
must be weighed against the significantly longer in vitro manufac-
turing process required to generate them (44). A clinical study of 
trispecific CTLs administered prophylactically after HSCT in the 
absence of immunosuppression demonstrated CMV-specific reac-
tivity in 70% of patients, and 40% of patients had detectable cir-
culating T cells to pp65-specific HLA pentamers with no increase 
in the incidence of GVHD. In this study, CMV- and EBV-specific 
T cell numbers rose in the absence of viral reactivation, but 
adenoviral-CTL expansion was only observed in the context of ade-
noviral infection (43). Bispecific CTLs generated by coculture with 
adenovirus-transduced MoDCs that were infused 28 days after 
HSCT delivered similar outcomes to those described above. All 
treated patients showed CMV-specific immunity, and 5 of 12 had 
T cells detectable by pp65-specific HLA pentamer analysis (42).
More recent studies have used nucleofection to introduce 
DNA plasmids encoding multiple immunogenic antigens from 
CMV, EBV, and adenovirus into APCs (45), or have used viral 
antigen–derived 15-mer peptide libraries (pepmix) with APCs to 
deliver a product with a broader CMV-reactive T cell repertoire 
(46). Extending the scope of antiviral adoptive cell transfer to 
simultaneously target three viruses has been shown to deliver sus-
tainable responses in patients, and the main reason for therapeutic 
failure is donor seronegativity (7). Table 2 summarizes some of the 
clinical trials of multi-VSTs in the post-HSCT setting.
Direct selection techniques. In generating novel immunothera-
pies for viral infection after HSCT, the two greatest clinical prior-
ities are the prevention of toxicity and the augmentation of clini-
cal responses. For these reasons, direct selection of CMV-specific 
T cells from donor samples is an attractive option when they are 
present at sufficiently high frequencies. Given the high frequen-
cies of circulating CMV-reactive T cells in seropositive individu-
als, direct selection is likely to yield sufficient starting material for 
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lation ex vivo induces T cell recall responses. IFN-γ–secreting T 
cells then undergo magnetic selection following labeling with an 
IFN-γ–targeted mAb conjugated to a leukocyte-specific (CD45) 
mAb. The resulting cellular product comprises CD4 and CD8 T 
cells recognizing multiple viral epitopes selected independently 
of HLA-specificity (unlike multimer-based selections). One clin-
ical study evaluated 18 patients with drug-refractory CMV vire-
mia after HSCT who had no prior history of GVHD. The mean T 
cell dose achieved in this study was 21.3 × 103/kg (albeit the dose 
did not correlate with in vivo expansion), and the CD4/CD8 ratio 
was 2:1. GVHD occurred in only 1 patient, and 15 of 18 patients 
had at least 1 log reduction in CMV DNA. In 12 evaluable patients, 
CMV-reactive T cells expanded in vivo, and in a subgroup, cells 
were still detectable at 6 months. In all 12 cases, there was either 
clearance or a significant reduction in CMV viremia (55).
A phase I/II study of IFN-γ catch technology generated pp65- 
specific T cells for 25 patients after HSCT. Sibling donor PBMCs 
were coincubated with recombinant pp65 or overlapping pp65 pep-
tides and were selected by immunomagnetic IFN-γ catch technology 
before administration in the prophylactic/preemptive setting. Prod-
ucts were generated for 25 patients, but were not infused in seven 
patients because of the presence of grade 1 or greater GVHD prior to 
infusion. In the prophylactic cohort, patients did not require antiviral 
pharmacotherapy over 6 months of follow-up. Of 11 patients treat-
ed preemptively, two required no antiviral pharmacotherapy and 
seven required only a single course of treatment. GVHD (greater 
than grade 1) arose de novo in 3 of 18 patients, but this was not asso-
ciated with product purity. Predictably, the predominant circulating 
CMV-reactive T cells at 4 weeks after infusion were effector memory 
and terminally differentiated effector cells (56).
Both multimer-based and IFN-γ catch–based selection pro-
cesses offer rapid GMP-compatible manufacture and scalability. 
Enrichment for virus-specificity may also limit the potential risks of 
alloimmunity. Potential limitations include the need for additional 
donor leukapheresis to collect sufficient starting material, which can 
be burdensome, particularly in the unrelated donor setting. Addi-
tionally, this method has a requirement for circulating VSTs, and is 
therefore not available to virus-naive donors or CMV-seropositive 
donors who do not respond to pp65 or IE-1 stimulation (57).
Third-party VSTs. In cases in which the donor graft is CMV- 
naive, manufacture of VSTs is more challenging. In this setting, 
third-party VSTs collected from virus-immune subjects with com-
mon HLA types represent a potential therapeutic option. Biobanks 
of cryopreserved VSTs can be swiftly accessed, and published data 
suggest that despite the degree of mismatch inherent in this strat-
egy, it is feasible, is associated with significant clinical responses, 
and does not precipitate high GVHD rates (58–61). In one clinical 
study, patients failing 7 days of viral pharmacotherapy for CMV 
reactivation after HSCT were eligible to receive an initial dose of up 
to 2 × 107 viral-specific T cells/m2, followed by 2 weekly infusions 
thereafter in the event of a response. Seventeen of 19 evaluable 
patients achieved a response (9 complete, 8 partial), 10 patients 
demonstrated expansion of CMV-reactive T cells in the blood, and 
de novo GVHD occurred in only 2 patients (60). This approach 
clearly represents an important development — firstly for patients 
who lack donor-derived VST options, and secondly for those who 
require urgent therapy and for whom the delays inherent in GMP 
manufacture of an individualized product are clinically inappropri-
ate. The trade-off comes by virtue of the degree of mismatch and 
the consequent possibility of shorter persistence and/or risks of 
alloimmunity, although the latter is not borne out by early studies.
New directions in CMV cellular therapies
T cells derived from virus-naive donors or cord blood are now 
being used as starting material to generate CMV-specific T cells in 
vitro with antigen presentation delivered through donor-derived 
pp65-transduced PBMCs or LCLs, or APCs incubated with pep-
mixes. Interestingly, epitope mapping reveals that CMV-reactive T 
cells generated in this way recognize different epitopes from those 
recognized by seropositive adult donors, but they still appear to be 
able to elicit a clinical response and confer protection (62, 63).
Gene modification of T cells by retroviral transduction 
with a synthetic CMV-specific TCR could offer an alternative 
option for patients with uncontrolled CMV infection and a CMV- 
seronegative donor (64). CMV-specific TCR-transduced T cells 
offer the potential advantages of a targeted therapy with a rela-
tively rapid manufacture process using naive starting material, but 
the disadvantages include high costs, feasibility issues, increased 
regulatory complexity, and the risk of viral immune escape by vir-
tue of targeting of a single epitope.
It is often the case that viral reactivation after HSCT arises in 
patients with GVHD receiving treatment with systemic immuno-
suppression. The efficacy and persistence of CMV-specific T cells 
have been shown to be compromised by corticosteroids (29), and 
for this reason, strategies to facilitate CMV-specific T cell resistance 
to commonly used immunosuppressive agents, and in particular 
corticosteroids, may be of critical importance to the field (65, 66).
EBV: biology and pathogenicity in the post-HSCT 
setting
EBV is a human herpesvirus with a seroprevalence of 95% in 
adults. Primary infection manifests as infectious mononucleosis, 
but following clinical recovery, EBV persists in latent form, pre-
dominantly in B cells. In the post-HSCT setting, gross impairment 
of T cell function liberates EBV-infected B cells (usually donor- 
derived) to outgrow, causing post-transplant lymphoproliferative 
disorder (PTLD). PTLD risk is particularly high in patients receiv-
ing enhanced immune suppression for the treatment of GVHD, 
and in those receiving anti-thymocyte globulin (57, 67).
The advent of PCR-based EBV monitoring, preemptive ther-
apy, and prompt administration of rituximab has made a huge 
impact on the mortality associated with PTLD after HSCT, 
although part of this reduction is attributable to ascertainment 
bias, and intervention in many who may have spontaneously 
cleared the virus. Despite these measures, up to one-third of 
patients with clinically apparent PTLD will succumb to uncon-
trolled disease, such that cellular therapeutic options are of great 
clinical relevance (68).
In considering potential immunotherapeutic approaches for 
PTLD, an understanding of the replicative cycle of EBV and latency- 
associated antigen expression is critical. Most healthy EBV- 
seropositive subjects have a broad repertoire of EBV-reactive T 
cells that mainly target the early-cycle lytic antigens. In the immu-
nocompromised patient after HSCT, highly immunogenic type 
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3 latency viral antigens such as Epstein-Barr nuclear antigen-2 
(EBNA-2), EBNA-3a, EBNA-3b, EBNA-3c, and EBNA-LP are seen 
in addition to type 1 latency antigens (EBNA-1) and type 2 latency 
antigens (latent membrane proteins 1 and 2 [LMP1 and LMP2]).
Immunotherapy and manufacture of EBV-
reactive T cells
The first clinical studies of immunotherapy for PTLD used unma-
nipulated donor lymphocyte infusions. Clinical responses were 
observed, but at the cost of significant toxicity from GVHD (69). 
The generation of a more virus-specific, less alloreactive therapy, 
EBV-specific T cells (EBVSTs), has followed similar strategies to 
those outlined for CMV. Initial studies using the B95-8 laboratory 
strain of EBV to develop LCLs demonstrated that these potent 
APCs can successfully expand EBVSTs ex vivo; administration of 
these cells induced clinical responses in patients. However, the 
use of live virus to generate patient products brings with it regu-
latory challenges (57, 70, 71). One further disadvantage of this 
method, particularly where there is urgent clinical need, is the 
long in vitro process (up to 3 months). Interestingly, the long cul-
ture period does not adversely affect EBVST persistence in vivo 
(72) and is also purported to reduce alloreactivity in vitro. In fact, 
any residual alloreactivity identified by in vitro assessment has not 
been shown to confer an increased risk of GVHD (73). Alternative 
methods to generate EBVSTs include use of whole viral proteins 
such as EBNA-1 to expand EBNA-1–specific VSTs, and this has 
been the subject of a phase I trial of PTLD after HSCT (74). To 
address the issues of prolonged in vitro processing, novel methods 
using direct cell selection via multimer binding and IFN-γ capture 
(EBNA-1–based stimulation) are also being explored (74).
Clinical responses to EBVSTs. There have been multiple clinical 
studies of EBVSTs generated by coculture with EBV-transformed 
LCLs for prophylaxis or treatment of PTLD. Across two major 
centers (St. Jude Children’s Research Hospital and Baylor College 
of Medicine), 114 patients received EBVSTs. The outcomes were 
impressive: of 101 treated patients receiving prophylaxis with 
EBVSTs, 0% developed PTLD compared with 11.5% in the control 
group. In a cohort with established PTLD, 11 of 13 treated patients 
achieved sustained complete response to treatment. Importantly, 
there were few short-term and no long-term toxicities associated 
with treatment: only 8 of 114 total treated patients experienced a 
recurrence of GVHD after EBVST treatment (70–72, 75). Similar 
response rates were observed in a cohort of patients with PTLD 
at the Memorial Sloan Kettering Cancer Center (MSKCC), where 
complete response was achieved in 10 of 14 treated patients (76). 
Notably, the Pavia group reported responses even in patients who 
had failed rituximab (77).
There is a minority of patients who fail to respond or lose their 
responses to EBVSTs. In some cases, EBV variants possess dele-
tions in immunodominant epitopes, such that EBVSTs generated 
against the WT epitope are unable to recognize and bind the 
variant epitope. The MSKCC group reported 3 patients who did 
not respond to EBVSTs: the transferred donor T cells recognized 
the B95-8–transformed LCLs, but not the EBV strain expressed 
on patient tumors. For one PTLD patient whose tumor derived 
from recipient (not donor) B cells, the fact that the synthesized 
donor EBVSTs skewed toward a donor-specific HLA antigen 
(A11011) that was not present on the recipient cells resulted 
in immune evasion. This patient subsequently responded to a 
third-party cell line (76). This case demonstrates the value of 
determining the origin of the tumor. See Table 3 for clinical tri-
als of donor-derived EBVSTs and Table 2 for a summary of clin-
ical studies of multi-VSTs.
EBV: off-the-shelf third-party cells. PTLD is an aggressive fast-
paced tumor that requires urgent treatment, and this must be cen-
tral to decision making about the source and manufacture methods 
used to generate EBVSTs. Banks of HLA-matched EBVSTs derived 
from healthy EBV-seropositive subjects are available where cells 
Table 3. Clinical studies using donor-derived EBV-specific T cells
Cell therapy No. of patients Date of study Activation Acute GVHD EBV-related outcome Ref.
Polyclonal EBV-specific T cells 1 1997 Coculture with EBV-LCL None reported No response 90
Polyclonal EBV-specific T cells 1 1998 Coculture with EBV-LCL Reactivation of acute skin GVHD CR 91
Polyclonal EBV-specific T cells 6 2000 Coculture with EBV-LCL None reported EBV DNA levels reduced in 5/6; 1 
death from PTLD
92
Polyclonal EBV-specific T cells 4 2007 Coculture with EBV-LCL None reported CR in 3 of 4 patients with PTLD 
recurrence post-rituximab; reduced 
EBV DNA in 1 patient without PTLD
77
Polyclonal EBV-specific T cells 113 2010 Coculture with EBV-LCL 8 recipients had recurrence of  
GVHD, but no de novo cases  
arose after CTL treatment
11/13 receiving treatment for PTLD 
achieved CR; prophylaxis prevented 
PTLD in 101/101
72A
Polyclonal EBV-specific T cells  
(gamma catch)
6 2010 Rapid expansion with 
peptides from 11 EBV 
antigens
None reported 3/6 complete responses 93
Polyclonal EBV-specific T cells 14 2012 Coculture with EBV-LCL None reported Established PTLD: 68% achieved 
durable CR
76
Polyclonal EBNA-1 protein–specific T 
cells (gamma catch)
10 2013 Rapid expansion using 
EBNA-1
1 Grade 2 GVHD Established EBV viremia ± PTLD: 
clinical and virological responses in 
7/10 cases
74
AIncorporates results of several other published studies (79, 80, 84). CTL, cytotoxic T lymphocyte; CR, complete response.
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apies that suggests their safety and efficacy, but without the robust 
confirmation of a phase III clinical study (as yet) to support this.
Strategies to select virus-specific cells to high purity have major 
implications for scalability and deliverability to a wider range of 
patients than can presently be treated using these methods. Novel 
developments that provide antiviral adoptive cell transfer options 
for HSCT patients with seronegative grafts also address an area of 
significant unmet clinical need.
It is clear that VSTs can potentially deliver clinical benefit 
and possess an acceptable safety profile. In order to move this 
technology into the mainstream, optimized GMP-grade deliv-
ery and infrastructure must be supported and developed. Work 
to transition antiviral T cell therapies from academic centers to 
commercial entities will help to facilitate broader implementa-
tion and improve accessibility of these therapies to patients and 
clinicians. This will also facilitate the larger randomized studies 
that are required to confirm efficacy, and to establish how these 
cellular therapies integrate with the newer antiviral pharmaco-
therapies. In this respect, studies of both HLA multimer–selected 
and third-party cells have been executed or initiated, the results of 
which will be crucial to establishing a more robust evidence base, 
particularly with regard to appropriate control groups. A greater 
focus on health care economics and reimbursement pathways will 
also be critical to the final positioning of these therapies in the 
overall treatment strategies for viral infections. Further analysis, 
characterization, and comparison of the phenotype and function 
of VSTs generated by different methods are also key, particularly 
given paradigm shifts in other T cell manufacturing processes to 
promote expansion, function, and persistence.
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are needed urgently. However, shorter persistence of these cells 
due to mismatching at one or more loci and alloreactivity are both 
risks. Published data suggest that the concept is feasible, that clini-
cal responses are possible or likely, and that GVHD does not occur 
at higher rates than in the control population (57, 59, 76).
An early study of third-party EBVSTs for PTLD after solid organ 
transplantation or HSCT screened EBVST donations before admin-
istration to confirm specific killing of donor LCLs as a surrogate read-
out for efficacy (78). Impressive clinical responses were reported: 
there was a reduction in tumor burden in 64% of treated patients 
at 5 weeks, which was maintained in 52% at 6 months of follow-up. 
There was no reported increase in the incidence of GVHD (59). Fur-
ther, using the same technology at another center, MSKCC observed 
clinical responses in 4 of 5 PTLD patients after HSCT (76, 79).
Overall response rates using third-party EBVSTs for PTLD 
(50%–70% responses) are slightly lower than that observed with 
donor-derived EBVSTs, but they nonetheless remain a therapeu-
tic option for a subgroup of PTLD patients. Multiple infusions or 
repeat dosing may be required because of the shorter persistence 
of these cells in vivo.
EBV: new directions. The high seroprevalence of EBV (greater 
than 95%) reminds us that strategies to manufacture EBVSTs from 
EBV-naive donors are less critical than strategies for CMV, whose 
population prevalence is as low as 50%. However, it is important 
to be able to manipulate cord blood for this purpose, and adenovi-
ral transfer vector–based transduction of APCs (including LCLs) 
can be used to generate de novo EBVSTs from cord blood grafts.
Other potential developments in EBV immunotherapy include 
gene modification of T cells by retroviral transduction with a syn-
thetic EBV-specific TCR. This could potentially offer an alternative 
option for patients with PTLD and an EBV-seronegative donor (80).
Conclusions and future directions
CMV and EBV primary infection and reactivation after HSCT can 
be formidable clinical problems for which effective pharmacother-
apeutics have substantial limitations. Accelerated reconstitution 
of antiviral immunity through adoptive cellular immunotherapy 
offers a more physiological solution.
In the setting of EBV-associated PTLD, clinical responses to 
EBVSTs are reported in 70%–90% of patients with minimal toxicity, 
and third-party cell banks now permit rapid administration in urgent 
cases. There is an expanding literature on CMV-specific T cell ther-
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